Amid claims of "digital dementia," experts explain that AI isn't declining. It's just stupid in the first place.

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study ...

For patients with mild cognitive impairment (MCI) associated with Alzheimer disease (AD), those in the highest tertile of the ...

Alzheimer’s Pipeline Report, released by the Kirk Kerkorian School of Medicine at UNLV, reveals dozens of promising drug trials that could bring hope to millions of families. The research ...

It wasn’t that long ago when screaming “follow the science” was all the rage, even if the alleged science wasn’t remotely ...

The gross proceeds from the Offering are approximately $19 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the ...

I remember the first time I was on stage and scrambled my words. If my lines in a play were supposed to be "Sherwin-Williams, ...

INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early ...

INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares ...

Santa Clarita-based Tombot Inc. nabbed $6.1 million in series A funding, the health robotics company announced in June.

Imagine losing your memories, your ability to recognize loved ones, or even perform daily tasks that once felt second nature. This is the painful reality for over 7 million Americans living with ...